BevCanna Enterprises



Cybin to Present at the Emerging Growth Conference on June 23rd

Cybin Selects Anxiety Disorder Indications for Proprietary Psychedelic Molecule CYB004

Cybin to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th

Cybin Launches EMBARK and Co-Sponsors First Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Burnout and Distress with Psychedelic-Assisted Psychotherapy

Cybin to Present at the 2021 LD Micro Invitational XI on June 10, 2021

Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine’s Psychedelic Effects on Cerebral Cortex Hemodynamics

Cybin to Present at the Jefferies Virtual Healthcare Conference 2021

Cybin Files an International Patent Application Further Strengthening its Psychedelic Derivative Drug Development Candidates Across 153 Global Jurisdictions

Cybin Files its 12th Patent Further Strengthening IP Portfolio of Novel Psychedelic Molecules and Delivery Mechanisms

Cybin Granted IRB Approval for Phase II Clinical Trials of its Sublingual Psilocybin Formulation for the Treatment of Major Depressive Disorder

Cybin to Present at the Benzinga Global Small Cap Conference

Cybin Selects Alcohol Use Disorder Indication for Psychedelic Molecule CYB003

Cybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the Treatment of Depression and Addiction

Cybin to Present at the Bloom Burton & Co. Healthcare Investor Conference

Cybin Establishes Clinical Advisory Board of Renowned Physicians, Dr. Maurizio Fava, Dr. Lynn Marie Morski and Dr. Anthony Back

Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications

Cybin Announces Senior Management Changes to Lead Buildout of Development and Clinical Capabilities in the United States and Europe

Cybin Inc. at Forefront of Psychedelic Revolution

Cybin Inc. in Prime Position as Interest in Psychedelic Medicine Surges

Cybin Signs Drug Development Agreement with Catalent for its Fast-Dissolve Formulation of Novel, Deuterated Tryptamine (CYB003)

Cybin Progresses Two Psychedelic Investigational New Drug (“IND”) Candidates and Announces Completion of Its 20th Pre-Clinical Study

Cybin to Present at the Oppenheimer 31st Annual Healthcare Conference

Cybin to Present at the M Vest and Maxim Group 2021 Emerging Growth Virtual Conference

Cybin to Present at the Stifel GMP Healthcare Conference – Healthcare Psychedelics: Addressing the Global Mental Health Crisis

Cybin Announces API Synthesis and Optimization of Multiple Tryptamine Derivatives and Nomination of Two Deuterated Candidates for Full IND Enabling Studies Based on Second Milestone Achievement Pursuant to the Adelia Acquisition

Cybin Inc. Shares Commence Trading on the OTCQB Venture Market on March 8, 2021

Cybin Inc. Announces Uplisting to OTCQB Venture Market


Filings Format Description Filing Date File/Film Number